News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
225,314 Results
Type
Article (7132)
Company Profile (16)
Press Release (218166)
Section
Business (63128)
Career Advice (294)
Deals (14767)
Drug Delivery (27)
Drug Development (36778)
Employer Resources (24)
FDA (6412)
Job Trends (4907)
News (121790)
Policy (11630)
Tag
Academia (564)
Alliances (14734)
Alzheimer's disease (575)
Approvals (6430)
Artificial intelligence (80)
Bankruptcy (146)
Best Places to Work (4609)
Breast cancer (89)
Cancer (885)
Cardiovascular disease (52)
Career advice (257)
CAR-T (73)
Cell therapy (185)
Clinical research (30785)
Collaboration (247)
Compensation (66)
COVID-19 (719)
C-suite (55)
Data (999)
Diabetes (83)
Diagnostics (2198)
Earnings (32710)
Events (30516)
Executive appointments (183)
FDA (6898)
Funding (211)
Gene therapy (111)
GLP-1 (159)
Government (1250)
Healthcare (6132)
Infectious disease (767)
Inflammatory bowel disease (55)
Interviews (45)
IPO (8007)
Job creations (570)
Job search strategy (220)
Legal (2093)
Lung cancer (126)
Lymphoma (58)
Manufacturing (81)
Medical device (4543)
Medtech (4544)
Mergers & acquisitions (7025)
Metabolic disorders (215)
Neuroscience (723)
NextGen: Class of 2025 (1500)
Non-profit (710)
Northern California (1009)
Obesity (114)
Opinion (70)
Parkinson's disease (47)
Patents (91)
People (14372)
Phase I (9814)
Phase II (13557)
Phase III (10155)
Pipeline (455)
Postmarket research (797)
Preclinical (3553)
Radiopharmaceuticals (115)
Rare diseases (136)
Real estate (999)
Regulatory (8991)
Research institute (509)
Southern California (860)
Startups (675)
United States (8496)
Vaccines (143)
Weight loss (65)
Date
Today (39)
Last 7 days (240)
Last 30 days (1137)
Last 365 days (16508)
2025 (1942)
2024 (16925)
2023 (19105)
2022 (22251)
2021 (23645)
2020 (21806)
2019 (14441)
2018 (10641)
2017 (11458)
2016 (9546)
2015 (11737)
2014 (8106)
2013 (5880)
2012 (6043)
2011 (6753)
2010 (6216)
Location
Africa (175)
Asia (17410)
Australia (4823)
California (2250)
Canada (969)
China (181)
Colorado (98)
Connecticut (137)
Delaware (43)
Europe (27615)
Florida (324)
Georgia (51)
Illinois (168)
Indiana (101)
Japan (73)
Maryland (285)
Massachusetts (1652)
Michigan (48)
Minnesota (87)
New Jersey (791)
New York (728)
North Carolina (336)
Northern California (1009)
Ohio (51)
Pennsylvania (547)
South America (300)
Southern California (860)
Texas (329)
Utah (51)
Virginia (57)
Washington State (305)
225,314 Results for "mesoblast limited".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Mesoblast Corporate Presentation at Investor Conference - June 03, 2024
Mesoblast Limited, Chief Executive Silviu Itescu provided a corporate update at the Bell Potter Emerging Leaders Conference.
June 2, 2024
·
5 min read
Press Releases
Mesoblast’s RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy
December 18, 2024
·
10 min read
Press Releases
Mesoblast to be Added to Nasdaq Biotechnology Index
December 19, 2024
·
5 min read
Policy
Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week
Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, confirmed that it will file its Biologics License Application for approval of Ryoncil® in the treatment of children with steroid-refractory acute graft versus host disease with the U.S. Food and Drug Administration next week.
July 1, 2024
·
4 min read
Cell therapy
Mesoblast Wins First Mesenchymal Stromal Cell Therapy FDA Approval for GVHD
The approval concludes what has been a difficult regulatory path for Ryoncil, which suffered FDA rejections in 2020 and 2023.
December 19, 2024
·
2 min read
·
Tristan Manalac
Pharm Country
Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer
Mesoblast Limited announced it has received firm commitments to complete its pro-rata accelerated non-renounceable entitlement offer that was launched on 4 December, 2023.
March 13, 2024
·
5 min read
Business
Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational update and reported financial results for the period ended December 31, 2023.
February 28, 2024
·
18 min read
Press Releases
Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease
December 19, 2024
·
5 min read
Press Releases
Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch
September 30, 2024
·
7 min read
Business
Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee
Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, announced that independent Director Jane Bell AM has been appointed Chair of the Mesoblast Board Audit and Risk Committee.
September 26, 2023
·
6 min read
1 of 22,532
Next
